FierceBiotech3d
Gilead's Daniel O'Day relishes Dietmar Berger reunion as cancer specialist agrees to join from Sanofi
Gilead Sciences has raided Sanofi for its next chief medical officer, luring Dietmar Berger, M.D., Ph.D., away from the ...
BioPharma Dive3d
Dietmar Berger is Gilead’s new CMO; Padlock investors sue Bristol Myers
Gilead CEO Daniel O’Day has hired Berger away from Sanofi. Elsewhere, Lonza is reorganizing and Bausch + Lomb is exploring a ...
ENDPOINTS NEWS3d
Gilead names Di­et­mar Berg­er CMO as it eyes R&D re­set
Gilead Sciences names Sanofi's Dietmar Berger as new CMO, replacing Merdad Parsey amid challenging year marked by setbacks ...
The Pharma Letter3d
Gilead Sciences names new CMO
US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief ...
GlobalData on MSN7d
Sanofi’s Phase III trial of rilzabrutinib for thrombocytopenia meets endpoint
Sanofi has reported that the Phase III LUNA 3 trial of rilzabrutinib for the treatment of persistent or chronic immune ...
The American Journal of Managed Care4d
Rare Blood Disease Innovations Address Unmet Needs, According to ASH Data
Innovations in rare blood disorders took center stage at the 2024 American Society of Hematology (ASH) Annual Meeting & ...
PMLiVE7d
Sanofi’s rilzabrutinib shows promise in phase 3 immune thrombocytopenia study
Sanofi has presented promising results from a phase 3 study of its investigational oral Bruton’s tyrosine kinase (BTK) ...
Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patientsNew analysis from the IMROZ phase 3 ...